The past decade has witnessed a wave of new medications to treat schizophrenia, a debilitating mental disorder that afflicts 1 in 100 people. Armed with results from their own studies, various pharmaceutical companies tout the new drugs, the so-called atypical antipsychotics, as superior to traditional antipsychotic drugs in the battle against schizophrenia.
However, it may be time to lower expectations for atypical antipsychotics.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.